Congestive Heart Failure (Heart Failure) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Congestive Heart Failure (Heart Failure) – Pipeline Review, H2 2019’, provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure)

– The report reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Congestive Heart Failure (Heart Failure) therapeutics and enlists all their major and minor projects

– The report assesses Congestive Heart Failure (Heart Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure)”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“4TEEN4 Pharmaceuticals GmbH

Actelion Pharmaceuticals Ltd

Adrenomed AG

AgeX Therapeutics Inc

Amgen Inc

Anchored Rsk3 Inhibitors LLC

Araim Pharmaceuticals Inc

ARCA biopharma Inc

Arena Pharmaceuticals Inc

Armaron Bio Pty Ltd

Armgo Pharma Inc

Ascelegen Therapeutics Inc

Ascendia Pharmaceuticals LLC

Astellas Pharma Inc

AstraZeneca Plc

Athersys Inc

Bayer AG

BEAT BioTherapeutics Corp

Betagenon AB

BioCardia Inc

BioStem Technologies Inc

BlueRock Therapeutics

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

C&C BioPharma LLC

Capricor Therapeutics Inc

Cardiol Therapeutics Inc

Cardior Pharmaceuticals GmbH

Cardiora Pty Ltd

CCRP Therapeutics GmbH

Celixir Ltd

CuronBiotech Inc

Cyclerion Therapeutics Inc

Daiichi Sankyo Co Ltd

DepYmed Inc

Elevian Inc

Ethicare GmbH

Exscien Corp

F. Hoffmann-La Roche Ltd

G3 Pharmaceuticals Inc

GBSciences Inc

Gmax Biopharm Ltd

Heartseed Inc

Hemostemix Inc

iHeart Japan Corp

Immunwork Inc

Innolife Co Ltd

Innopharmax Inc

Inserm Transfert SA

Intra-Cellular Therapies Inc

IsletOne AB

Japan Tobacco Inc

JT Pharmaceuticals Inc

Juventas Therapeutics Inc

Katakura Industries Co Ltd

KBP BioSciences Co Ltd

La Jolla Pharmaceutical Company

Larix Bioscience LLC

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lexicon Pharmaceuticals Inc

Merck & Co Inc

Mesoblast Ltd

Mirabilis Therapeutics BV

Miragen Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

Moderna Therapeutics Inc

MyoKardia Inc

Nanjing Transthera Biosciences Co Ltd

NanoCor Therapeutics Inc

NeoProgen Inc

Novartis AG

NovoMedix LLC

Olatec Therapeutics LLC

Orion Corp

Otsuka Holdings Co Ltd

Oxstem Ltd

Oxydend Therapeutics Pty Ltd

Palatin Technologies Inc

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Pharchoice Therapeutics Inc

PharmaIN Corp

PhaseBio Pharmaceuticals Inc

Phrixus Pharmaceuticals Inc

Prolifagen LLC

Proveca Ltd

Q BioMed Inc

Quantum Genomics SA

Qurgen Inc

Recardio GmbH

Renova Therapeutics Inc

resTORbio Inc

Ribomic Inc

Rnatives Ltd

Saje Pharma LLC

Sanofi

Sarfez Pharmaceuticals Inc

Senju Pharmaceutical Co Ltd

Shanghai Life Science & Technology

Shenzhen Salubris Pharmaceuticals Co Ltd

Shin Poong Pharm Co Ltd

Signal Pharma Ltd

Silver Creek Pharmaceuticals Inc

Sorrento Therapeutics Inc

Stemedica Cell Technologies Inc

Sumocor LLC

Sun Pharma Advanced Research Company Ltd

T&R Biofab Co Ltd

Takeda Pharmaceutical Co Ltd

Tenaya Therapeutics Inc

Theravance Biopharma Inc

Toa Eiyo Ltd

Torrent Pharmaceuticals Ltd

TreeFrog Therapeutics SAS

Trio Medicines Ltd

U.S. Stem Cell Inc

Viera BioScience Inc

Vifor Pharma Ltd

Viscofan BioEngineering

Windtree Therapeutics Inc

Xcelthera INC

Xogenex LLC

XyloCor Therapeutics Inc

Zensun (Shanghai) Sci & Tech Co Ltd”

Table of Contents

Table of Contents

Table of Contents

Introduction

Congestive Heart Failure (Heart Failure) Overview

Congestive Heart Failure (Heart Failure) Therapeutics Development

Congestive Heart Failure (Heart Failure) Therapeutics Assessment

Congestive Heart Failure (Heart Failure) Companies Involved in Therapeutics Development

Congestive Heart Failure (Heart Failure) Drug Profiles

Congestive Heart Failure (Heart Failure) Dormant Projects

Congestive Heart Failure (Heart Failure) Discontinued Products

Congestive Heart Failure (Heart Failure) Product Development Milestones

Appendix

List of Tables

“List of Tables

Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by 4TEEN4 Pharmaceuticals GmbH, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Actelion Pharmaceuticals Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Adrenomed AG, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by AgeX Therapeutics Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Amgen Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Anchored Rsk3 Inhibitors LLC, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Araim Pharmaceuticals Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by ARCA biopharma Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Arena Pharmaceuticals Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Armaron Bio Pty Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Armgo Pharma Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Ascelegen Therapeutics Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Ascendia Pharmaceuticals LLC, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Astellas Pharma Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by AstraZeneca Plc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Athersys Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Bayer AG, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by BEAT BioTherapeutics Corp, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Betagenon AB, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by BioCardia Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by BioStem Technologies Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by BlueRock Therapeutics, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Bristol-Myers Squibb Co, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by C&C BioPharma LLC, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Capricor Therapeutics Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Cardiol Therapeutics Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Cardior Pharmaceuticals GmbH, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Cardiora Pty Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by CCRP Therapeutics GmbH, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Celixir Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by CuronBiotech Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Cyclerion Therapeutics Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Daiichi Sankyo Co Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by DepYmed Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Elevian Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Ethicare GmbH, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Exscien Corp, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by G3 Pharmaceuticals Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by GBSciences Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Gmax Biopharm Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Heartseed Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Hemostemix Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by iHeart Japan Corp, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Immunwork Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Innolife Co Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Innopharmax Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Inserm Transfert SA, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Intra-Cellular Therapies Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by IsletOne AB, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Japan Tobacco Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by JT Pharmaceuticals Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Juventas Therapeutics Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Katakura Industries Co Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by KBP BioSciences Co Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by La Jolla Pharmaceutical Company, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Larix Bioscience LLC, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Lead Discovery Center GmbH, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Les Laboratoires Servier SAS, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Lexicon Pharmaceuticals Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Merck & Co Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Mesoblast Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Mirabilis Therapeutics BV, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Miragen Therapeutics Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Moderna Therapeutics Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by MyoKardia Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Nanjing Transthera Biosciences Co Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by NanoCor Therapeutics Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by NeoProgen Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Novartis AG, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by NovoMedix LLC, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Olatec Therapeutics LLC, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Orion Corp, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Otsuka Holdings Co Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Oxstem Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Oxydend Therapeutics Pty Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Palatin Technologies Inc, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2019

Congestive Heart Failure (Heart Failure) – Pipeline by Pfizer Inc, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports